Early data readout indicates a successful LPS human challenge trial
Poolbeg Pharma PLC (AIM:POLB) identifies novel RSV drug candidates
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Poolbeg Pharma PLC (AIM:POLB) Metabolic diseases oral delivery licence signed
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
Poolbeg Pharma PLC (AIM:POLB) POLB 001 LPS human challenge trial completed
POLB 001 LPS human challenge clinical trial successfully completed
Poolbeg Pharma PLC (AIM:POLB) Influenza Artificial Intelligence model build completed
CytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023
Poolbeg Pharma PLC (AIM:POLB) Capital Markets Day
17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it
Poolbeg Pharma PLC (AIM:POLB) Poolbeg-led consortium awarded €2.3m in non-dilutive funding to progress Oral Vaccine Platform
Transformative oral vaccine platform funded by the Disruptive Technologies Innovation Fund
Poolbeg Pharma PLC (AIM:POLB) AI programme yields novel RSV drug targets
Artificial intelligence programme yields multiple novel RSV drug targets
Poolbeg Pharma PLC (AIM:POLB) Upcoming Events
21 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, announces that its management and business development
Poolbeg Pharma PLC (AIM:POLB) CEO Share Purchase
6 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been
Poolbeg Pharma PLC (AIM:POLB) POLB 001 US Patent update
Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline